ASCO

Aug 13, 2024

For most of the last century, breast cancer was categorized only by its location in the body; as a result, treatment results varied significantly. Patients with metastatic HER2+ breast cancer were traditionally treated with conventional chemotherapy regimens until trastuzumab became available. In September 1998, th...

Nov 17, 2023

Lung cancer is the leading cause of cancer death in both men and women around the world. It is expected that 127K people will die from this disease in the United States in 2023 (67K men and 60K women).  NSCLC is the most common type of lung cancer, accounting for over 85% of all cases. As per DelveInsight anal...

Feb 24, 2023

The ASCO Genitourinary (GU) Cancers Symposium, which ended on February 18, 2023, was a three-day scientific and educational meeting designed to provide attendees with in-depth, multidisciplinary analysis of the timely topics in the study, diagnosis, and treatment of GU malignancies. DelveInsight has compiled the sy...

Mar 03, 2022

Enhertu with Opdivo exhibited clinical efficacy with an ORR of 36.7% in HER2+ urothelial cancer in Phase Ib study On the second day of ASCO-GU 2022, the rapid abstract session highlighted the results from the DS8201-A-U105 trial (NCT03523572; Active, not recruiting) of Enhertu (trastuzumab deruxtecan) with Opdiv...

Feb 25, 2022

Phase II study of neoadjuvant cabozantinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma Based on the findings from the Phase II study (NCT04022343), neoadjuvant cabozantinib was safe and induced a reduction in tumor size in all patients with locally advanced nonmetastatic ccRC...

Feb 25, 2022

Padcev (Enfortumab vedotin) for the treatment of locally advanced or metastatic urothelial cancer, Adcetris (Brentuximab vedotin) for the treatment of several types of CD30-expressing lymphomas, and Tivdak (Tisotumab vedotin) for the treatment of recurrent or metastatic cervical cancer are the three ADCs that Seage...

Feb 24, 2022

Use of CAR-T treatments and their efficacy in Prostate Cancer We already know that Immunotherapies have not performed well in the treatment of prostate cancer. Such medicines have failed to elicit a long-term response in patients with advanced prostate cancer. Surgery, radiation treatment, chemotherapy, androgen...

Feb 24, 2022

Major Key player Arvinas announced completed Phase I and interim Phase II ARDENT data for ARV-110 degrader targeting the androgen receptor (AR). According to the results, Arvinas mentioned that at the data cut-off date, December 20, 2021, the PSA50 response rate was 46% in 28 patients with AR T878X/H875Y tumor muta...

Feb 22, 2022

According to the findings of the ARASENS trial (NCT02799602), presented by Bayer at the 2022 ASCO GU, Nubeqa resulted in a 32.5% reduction in the risk of death, with a median follow-up of 43.7 months for darolutamide.  Nubeqa provided a consistent overall survival advantage across predefined subgroups. The med...

Feb 22, 2022

Preliminary findings of Phase I/II dose-expansion study of DS-7300 (a B7-H3 antibody-drug conjugate) in mCRPC patients backed B7-H3 as a potential new target in treatment-resistant prostate cancers (Abstract #87) Immune-checkpoint inhibitors (ICI) have resulted in significant therapeutic advancements in a wide r...